DXRX Diaceutics Plc

TIDMDXRX

RNS Number : 9743M

Diaceutics PLC

26 May 2022

26 May 2022

Diaceutics PLC

("Diaceutics" or "the Company")

Results of Annual General Meeting

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, is pleased to announce that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed by a show of hands.

The proxy votes received from shareholders in respect of each resolution are set out below and are available on the Company's website, www.diaceutics.com .

 
 Resolution                                       For (excluding              Against           Total      Withheld 
                                               at Chair's discretion)                         votes cast 
                                                Number           %        Number       %                   Number of 
                                                of votes                  of votes                           votes 
    --------------------------------------  --------------  ----------  ----------  ------  ------------  ----------- 
     Ordinary resolution 
      to receive and consider 
      the 2021 Financial 
 1    Statements                                62,700,675     100.00%           0   0.00%    62,700,675       Nil 
    --------------------------------------  --------------  ----------  ----------  ------  ------------  ----------- 
     Ordinary resolution 
      to approve the directors' 
 2    remuneration report                       62,693,325      99.99%       7,350   0.01%    62,700,675      Nil 
    --------------------------------------  --------------  ----------  ----------  ------  ------------  ----------- 
     Ordinary resolution 
      to re-elect Nick Roberts 
 3    as a director                             62,700,675     100.00%           0   0.00%    62,700,675      Nil 
    --------------------------------------  --------------  ----------  ----------  ------  ------------  ----------- 
     Ordinary resolution 
      to re-elect Charles 
 4    Hindson as a director                     61,651,904      98.32%     900,000   1.44%    62,551,904      Nil 
    --------------------------------------  --------------  ----------  ----------  ------  ------------  ----------- 
     Ordinary resolution 
      to re-appoint PricewaterhouseCoopers 
 5    LLP as auditors                           62,550,243      99.75%       1,661   0.01%    62,551,904      Nil 
    --------------------------------------  --------------  ----------  ----------  ------  ------------  ----------- 
     Ordinary resolution 
      to authorise the directors 
      to determine the remuneration 
 6    of the auditors                           62,700,675     100.00%           0   0.00%    62,700,675       Nil 
    --------------------------------------  --------------  ----------  ----------  ------  ------------  ----------- 
     Ordinary resolution 
      to authorise the directors 
 7    to allot shares                           62,699,175     100.00%           0   0.00%    62,700,675      1,500 
    --------------------------------------  --------------  ----------  ----------  ------  ------------  ----------- 
     Special resolution 
      to authorise the directors 
      to disapply pre-emption 
 8    rights                                    62,697,164       99.9%       2,011   0.01%    62,699,175      1,500 
    --------------------------------------  --------------  ----------  ----------  ------  ------------  ----------- 
     Special resolution 
      to authorise the directors 
 9    to purchase own shares                    60,606,084      99.99%       8,661   0.01%    62,614,745    2,085,930 
    --------------------------------------  --------------  ----------  ----------  ------  ------------  ----------- 
 

Enquiries:

 
Diaceutics PLC 
Peter Keeling, Chief Executive Officer                       Via Alma PR 
Nick Roberts, Chief Financial Officer 
 
Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 
                                                                    7600 
Ben Maddison, Stewart Wallace, Nick Adams 
 
Alma PR                                               Tel: +44(0)20 3405 
                                                                    0205 
Caroline Forde, Kieran Breheny, Matthew Young    diaceutics@almapr.co.uk 
 

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network(R).

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGKZGZKFVKGZZM

(END) Dow Jones Newswires

May 26, 2022 10:00 ET (14:00 GMT)

Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024

Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024